Article Text

PDF
A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma
  1. A C S How1,
  2. R S Kumar2,
  3. Y-M Chen3,
  4. D H Su1,
  5. H Gao3,
  6. F T Oen1,
  7. C-L Ho1,
  8. S K Seah1,
  9. T Aung1,2,4
  1. 1
    Singapore National Eye Centre, Singapore
  2. 2
    Singapore Eye Research Institute, Singapore
  3. 3
    Clinical Trials and Epidemiology Research Unit, Singapore
  4. 4
    Yong Loo Lin School of Medicine, National University of Singapore, Singapore
  1. Dr T Aung, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751; tin11{at}pacific.net.sg

Abstract

Background/aims: To compare the intraocular pressure (IOP) lowering efficacy and side effects of latanoprost 0.005% and bimatoprost 0.03% in subjects with chronic primary angle closure glaucoma (PACG).

Methods: This was an observer-masked randomised crossover study of 60 PACG subjects who received either latanoprost or bimatoprost for 6 weeks, after which they were crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications was assessed by the reduction in IOP after 6 weeks of treatment compared with baseline.

Results: Fifty-four subjects (80 eyes) completed the study. Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23). Adverse events were mild in both groups; however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01). Ocular irritation was the most frequently reported adverse event in both groups; 22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).

Conclusions: Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG. Both drugs were well tolerated with mild ocular adverse events.

Statistics from Altmetric.com

Footnotes

  • Competing interests: TA has received research funding, travel support and honoraria from Allergan and has been a consultant and received travel support and honoraria from Pfizer.

  • Funding: This research was funded by an unrestricted grant from Allergan.

  • Ethics approval: Ethics approval was provided by the Ethics Committee of the Singapore Eye Research Institute.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh